StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Trading Down 6.3 %

Shares of NSPR stock opened at $2.82 on Wednesday. The firm has a market capitalization of $73.55 million, a PE ratio of -4.01 and a beta of 0.98. The firm has a fifty day simple moving average of $2.61 and a two-hundred day simple moving average of $2.65. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the previous year, the business posted ($0.15) EPS. On average, equities analysts predict that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

Institutional investors have recently made changes to their positions in the company. Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD in the 3rd quarter worth $279,000. Affiance Financial LLC bought a new stake in shares of InspireMD in the 3rd quarter worth $492,000. Finally, Rosalind Advisors Inc. grew its stake in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after acquiring an additional 1,827,579 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.